TMO vs VRTX
TMO: Global leader in life sciences tools, diagnostics, and laboratory services supporting research, diagnostics, and bioproduction across pharma, biotech, and clinical markets. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | TMO | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $524.71 | $498.43 | |
| Market cap as of 2026-07-10 | $193.1B | $130.3B | |
| P/E as of 2026-07-10 | 28.21 | 30.05 | TMO lower |
| PEG as of 2026-07-10 | 2.89 | 2.31 | VRTX lower |
| Net margin as of 2026-07-10 | +15.2% | +35.5% | VRTX higher |
| Gross margin as of 2026-07-10 | +40.9% | +86.2% | VRTX higher |
| Operating margin as of 2026-07-10 | +17.5% | +38.3% | VRTX higher |
| ROE as of 2026-07-10 | +13.2% | +23.9% | VRTX higher |
| ROA as of 2026-07-10 | +6.4% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-10 | 0.83 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-07-10 | +5.4% | +10.1% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +10.4% | VRTX higher |
| Dividend yield as of 2026-07-10 | +0.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-10 | 0.86 | 0.29 | |
| 1-year return as of 2026-07-09 close | +25.0% | +6.9% | TMO higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.